Some MMEX facts to consider: Most recently, Mad J.

New Post Public Reply Private Reply Replies (1) Message Board
jmjjw
430
Some MMEX facts to consider:

Most recently, Mad J. suggests that $88-million in project financing funds are necessary for the Phase I project (whatever that now is). Using the vague information MMEX has released, this is to be an 80/20 debt/equity deal.

We already know that Mad J., primarily through gross negligence and total incompetence overran an initial cost estimate of <$49-million. Ignoring the intermediate errors, the difference is $39-million, a 44% cost overrun before ever bending a plate.

Given the delays, ineptitude, and utter incompetence, along with history, it isn’t unreasonable to expect that Mad J.’s current estimate is off by at least 20% - which brings the Phase I cost to something north of $100-million.

Given math isn’t the strong suit for the MMEX advocates, that means the equity component of the deal ranges from $17.6-million to more than $20-million.

So far, in more than a year, Mad J. has managed to raise a bit more than $2.1-million - all of that in the form of floor-less, convertible toxic debt - most of which has been siphoned off in the form of “SG&A expense” and related-party transactions. That’s about 10% of the required equity raise, in round numbers, in about 18-months.

There’s no evidence, other than vague claims in shareholder letters, about a now-expired “terms sheet” from an unnamed “international debt fund,” about the 80% debt component source.

There’s zero evidence about a $20-ish million private equity raise - no deal teams, no financial industry news, no prospectus in the PE markets, no nothing.

In parallel, recall that MMEX is a super-dilutive, insolvent OTC shell company, with no business operations, employees, or assets. MMEX has nearly $40-million in cumulative losses, and current liabilities.

MMEX has no intellectual property, and owns no proprietary technology. MMEX has no suppliers, and no customers. MMEX has no luminary management, or technology team.

MMEX has a single permit, now invalid, due to incompetence. MMEX’s site, a 126-acre parcel of isolated desert land has no pipeline access for crude or refined products transmission. The road distance from Permian crude sources is long, and the rail line adjacent is deprecated.

MMEX’s business plan is so heavily flawed an undergraduate student could torpedo it to the abyss.

MMEX’s founder is a con-man, a grifter, with a 30+ year history of loss generation, fraud, and malfeasance.

Those are the positives.

So, someone stand up, honestly, and delineate exactly how a company like MMEX is eligible for $88-million to $100-million or more in legitimate capital financing. Please use facts, and verifiable references.

MMEX Resources Corporation (MMEX) Stock Research Links

MMEX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Russel Metals Shows Strong Performance in Latest Earnings Report

Updated Category News Views 240

Russel Metals Inc. Reports Third Quarter Results for 2025 Russel Metals Inc. (TSX:RUS) has recently shared its financial performance for the three-month period ending September 30, 2025. The results reflect a positive trajectory in revenue and strategic initiatives to enhance its market position. Key Financial Metrics Overview In this quarter, Russel Metals has...

Continue Reading
KBC Group Shows Strong Capital Resilience Ahead of Changes

Updated Category News Views 257

KBC Group's Capital Position Remains Strong KBC Group has reported a robust standing in its capital levels, significantly exceeding the minimum capital requirements mandated by the European Central Bank (ECB). As part of the Supervisory Review and Evaluation Process (SREP) scheduled for the upcoming year, KBC received formal notification regarding its capital metrics....

Continue Reading
Synlogic's Q3 Financial Update Highlights Strategic Review

Updated Category News Views 79

Synlogic Provides Third Quarter 2024 Financial Results Synlogic, Inc. (NASDAQ: SYBX), a prominent biopharmaceutical firm dedicated to developing innovative therapeutics for serious diseases, has recently outlined its financial performance for the third quarter of 2024. The organization is actively working on advancing its mission to enhance healthcare through...

Continue Reading
Incannex Healthcare Sees Growth with Positive Fiscal Results

Updated Category News Views 98

Incannex Healthcare's Remarkable Financial Progress Incannex Healthcare Inc. (NASDAQ: IXHL) is making impressive strides in the biopharmaceutical world, focusing on breakthrough treatments for chronic diseases. Their recent fiscal year report outlines not only financial outcomes but also a plethora of operational and clinical advancements aimed at addressing significant...

Continue Reading
Revolutionizing Finance with ChatAnalyst at Alpha Liquid Terminal

Updated Category News Views 167

Alpha Liquid Terminal Introduces ChatAnalyst Financial Agent Recently, a game-changing tool was launched that promises to redefine how individuals manage and interpret financial data. This is powered by the innovative company, Alpha Liquid Terminal. The newly unveiled AI-driven financial analyst agent, known as ChatAnalyst, is designed to simplify and streamline financial...

Continue Reading